High cholesterol is a widespread health concern, affecting over half of British adults, where fatty substances accumulate in the blood and can clog arteries. This condition is a significant risk factor for heart disease, often associated with poor diet, lack of exercise, smoking, and obesity, ultimately increasing the risk of heart attacks and strokes. Traditionally, cholesterol levels are assessed by measuring low-density lipoprotein (LDL-C), commonly referred to as 'bad' cholesterol. However, this method does not directly quantify the number of harmful particles, known as apolipoprotein B (apoB), that are responsible for arterial damage.

A recent study by researchers from Northwestern Medicine in the US suggests that measuring apoB could be a more effective and life-saving approach than standard cholesterol tests. The apoB test, which is currently not routinely used within the NHS but costs around £36 at private clinics, directly measures the concentration of these harmful particles in the blood. This allows medical professionals to prescribe timely interventions, such as medication or lifestyle modifications, potentially years before a patient develops serious cardiovascular illness.

To evaluate the efficacy of apoB testing, researchers developed a simulation model involving 250,000 US adults who were eligible for statins—medications designed to lower bad cholesterol—but had not yet been diagnosed with cardiovascular disease. The study projected the outcomes if doctors based medication prescriptions on levels of 'bad' LDL cholesterol, non-HDL cholesterol (encompassing all forms of cholesterol), or apoB. The findings revealed that focusing on apoB markers could prevent approximately 1,000 more heart attacks and strokes per 250,000 people compared to existing testing methodologies. This proactive approach could also lead to significant cost savings for health providers by reducing the need for expensive emergency care and long-term recovery for heart patients.

Published in the prestigious journal JAMA, the study strongly advocates for the broader implementation of apoB testing to enhance treatment decisions. Ciaran Kohli-Lynch, the lead author and assistant professor of preventive medicine at Northwestern University, emphasized, 'We found that apoB testing to intensify cholesterol-lowering medication would prevent more heart attacks and strokes than current practice.' While experts have called for the NHS to adopt this test more widely, some, like Dr. Richard Webb from Liverpool Hope University, suggest integrating the apoB test alongside current practices. Dr. Webb noted that some patients might have normal LDL cholesterol results, providing a false sense of security, despite still being at risk due to elevated apoB levels, often linked to poor diet and predisposition to chronic diseases. Although the number of such 'missed' patients may be relatively small, it could still amount to thousands of individuals unaware of their heightened risk of heart attack.